Find Erlotinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 183321-74-6, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, Tarceva, Erlotinib free base, 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline, Osi-774
Molecular Formula
C22H23N3O4
Molecular Weight
393.4  g/mol
InChI Key
AAKJLRGGTJKAMG-UHFFFAOYSA-N
FDA UNII
J4T82NDH7E

Erlotinib
A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.
Erlotinib is a Kinase Inhibitor. The mechanism of action of erlotinib is as a Protein Kinase Inhibitor.
1 2D Structure

Erlotinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
2.1.2 InChI
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
2.1.3 InChI Key
AAKJLRGGTJKAMG-UHFFFAOYSA-N
2.1.4 Canonical SMILES
COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
2.2 Other Identifiers
2.2.1 UNII
J4T82NDH7E
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 11c Erlotinib

2. 11c-erlotinib

3. 358,774, Cp

4. 358774, Cp

5. Cp 358,774

6. Cp 358774

7. Cp-358,774

8. Cp-358774

9. Cp358,774

10. Cp358774

11. Erlotinib Hcl

12. Erlotinib Hydrochloride

13. Hcl, Erlotinib

14. Hydrochloride, Erlotinib

15. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

16. Osi 774

17. Osi-774

18. Osi774

19. Tarceva

2.3.2 Depositor-Supplied Synonyms

1. 183321-74-6

2. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

3. Tarceva

4. Erlotinib Free Base

5. 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline

6. Osi-774

7. 4-quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-

8. Erlotinib, Free Base

9. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine

10. 183321-74-6 (free Base)

11. Nsc 718781

12. Chembl553

13. J4t82ndh7e

14. [6,7-bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine

15. Cp358774

16. Cp-358,774

17. Chebi:114785

18. Mfcd02089651

19. Rg-1415

20. Ncgc00164574-01

21. [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine

22. Cp-35877401

23. R-1415

24. Dsstox_cid_26454

25. Dsstox_rid_81628

26. Dsstox_gsid_46454

27. Erlotinib(tarceva)

28. Osi-744

29. Cas-183321-74-6

30. Nsc718781

31. Erlotinib [inn:ban]

32. Sr-05000001460

33. Unii-j4t82ndh7e

34. Erlotinibum

35. Erotinib

36. Hsdb 8082

37. Osi 744

38. Nchembio866-comp3

39. Kinome_3317

40. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride

41. Erlotinib [mi]

42. Erlotinib [vandf]

43. R 1415

44. Erlotinib [who-dd]

45. Schembl8413

46. Erlotinib [ema Epar]

47. Bdbm5446

48. Cid_176870

49. Gtpl4920

50. Dtxsid8046454

51. Hms2089f05

52. Hms3244m19

53. Hms3244m20

54. Hms3244n19

55. Hms3295a19

56. Hms3713c22

57. Hms3745m05

58. Zinc1546066

59. Tox21_112202

60. Ac-399

61. Nsc800097

62. S7786

63. Stk623143

64. Akos000282911

65. Tox21_112202_1

66. Ccg-220420

67. Cs-0620

68. Db00530

69. Nsc-800097

70. Ro-508231

71. Sb16916

72. Ncgc00164574-03

73. Ncgc00164574-05

74. Ncgc00164574-06

75. Ncgc00164574-14

76. Ncgc00164574-25

77. As-35132

78. Bcb03_000783

79. Be164419

80. Hy-50896

81. Sy028059

82. Am20090621

83. Ft-0651539

84. R1415

85. K00241

86. Ab01273955-01

87. Ab01273955-02

88. Ab01273955-03

89. 321e746

90. Q418369

91. Sr-05000001460-1

92. Sr-05000001460-2

93. Sr-05000001460-3

94. Sr-05000001460-6

95. Brd-k70401845-003-04-7

96. 1429636-49-6

2.4 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 393.4 g/mol
Molecular Formula C22H23N3O4
XLogP33.3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count11
Exact Mass393.16885622 g/mol
Monoisotopic Mass393.16885622 g/mol
Topological Polar Surface Area74.7 Ų
Heavy Atom Count29
Formal Charge0
Complexity525
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameTarceva
PubMed HealthErlotinib (By mouth)
Drug ClassesAntineoplastic Agent, Immunological Agent
Drug LabelTARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti...
Active IngredientErlotinib hydrochloride
Dosage FormTablet
RouteOral
Strengtheq 100mg base; eq 150mg base; eq 25mg base
Market StatusPrescription
CompanyOsi Pharms

2 of 2  
Drug NameTarceva
PubMed HealthErlotinib (By mouth)
Drug ClassesAntineoplastic Agent, Immunological Agent
Drug LabelTARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti...
Active IngredientErlotinib hydrochloride
Dosage FormTablet
RouteOral
Strengtheq 100mg base; eq 150mg base; eq 25mg base
Market StatusPrescription
CompanyOsi Pharms

4.2 Therapeutic Uses

Erlotinib hydrochloride monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for TARCEVA (erlotinib hydrochloride) tablet (April 2012). Available from, as of November 10, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20


Erlotinib hydrochloride monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for TARCEVA (erlotinib hydrochloride) tablet (April 2012). Available from, as of November 10, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20


Erlotinib hydrochloride in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for TARCEVA (erlotinib hydrochloride) tablet (April 2012). Available from, as of November 10, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20


4.3 Drug Warning

The manufacturer states that there are no known contraindications to the use of erlotinib.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 1040


Serious, sometimes fatal, interstitial lung disease-like events have occurred in patients receiving erlotinib. Interstitial lung disease-like events have been reported in approximately 0.7% of about 4900 patients receiving erlotinib in controlled and uncontrolled studies. In the principal efficacy study for non-small cell lung cancer, the reported incidence of interstitial lung disease-like events (0.8%) was similar among patients receiving erlotinib and those receiving placebo. In the principal efficacy study for pancreatic cancer, interstitial lung disease-like events occurred in 2.5% of patients receiving erlotinib and gemcitabine versus 0.4% of those receiving placebo and gemcitabine. Onset of manifestations occurred from 5 days to more than 9 months (median: 39 days) after initiating erlotinib therapy. Reported diagnoses in patients suspected of having interstitial lung disease-like events included pneumonitis, radiation pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, pulmonary fibrosis, acute respiratory distress syndrome, and lung infiltration. Among patients receiving erlotinib for non-small cell lung cancer, most of these cases were associated with confounding or contributing factors, including concomitant or prior chemotherapy, prior radiotherapy, preexisting parenchymal lung disease, metastatic lung disease, or pulmonary infections.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 1040


Interruption or discontinuance of erlotinib therapy may be required in patients experiencing pulmonary toxicity.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 1040


Hepatorenal syndrome or acute renal failure, sometimes fatal, and renal insufficiency, with or without hypokalemia, have been reported in patients receiving erlotinib. Factors contributing to these adverse renal effects included baseline hepatic impairment; severe dehydration caused by diarrhea, vomiting, and/or anorexia; and concurrent chemotherapy. If dehydration occurs, erlotinib therapy should be interrupted and rehydration measures should be initiated. Periodic monitoring of renal function and serum electrolytes is recommended in patients at risk of dehydration.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 1040


For more Drug Warnings (Complete) data for Erlotinib (27 total), please visit the HSDB record page.


4.4 Drug Indication

Erlotinib is indicated for: - The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. - In combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer. The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.


FDA Label


* Non-small cell lung cancer (NSCLC):

Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.

Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.

When prescribing Tarceva, factors associated with prolonged survival should be taken into account.

No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours.

* Pancreatic cancer :

Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer .

When prescribing Tarceva, factors associated with prolonged survival should be taken into account.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
ERLOTINIB
5.2.2 FDA UNII
J4T82NDH7E
5.2.3 Pharmacological Classes
Protein Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]
5.3 ATC Code

L01EB02


L01XE03

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors

L01EB02 - Erlotinib


5.4 Absorption, Distribution and Excretion

Absorption

Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH dependent. Solubility decreases pH increases. Smoking also decrease the exposure of erlotinib.


Route of Elimination

Following a 100 mg oral dose, 91% of the dose was recovered in which 83% was in feces (1% of the dose as unchanged parent compound) and 8% in urine (0.3% of the dose as unchanged parent compound).


Volume of Distribution

Apparent volume of distribution = 232 L


Clearance

Smokers have a 24% higher rate of erlotinib clearance.


Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH dependent. Erlotinib solubility decreases as pH increases.

US Natl Inst Health; DailyMed. Current Medication Information for TARCEVA (erlotinib hydrochloride) tablet (April 2012). Available from, as of November 10, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20


Following absorption, erlotinib is approximately 93% protein bound to plasma albumin and alpha-1 acid glycoprotein. Erlotinib has an apparent volume of distribution of 232 liters.

US Natl Inst Health; DailyMed. Current Medication Information for TARCEVA (erlotinib hydrochloride) tablet (April 2012). Available from, as of November 10, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20


Time to reach steady state plasma concentration /is/ 7 - 8 days. No significant relationships of clearance to covariates of patient age, body weight or gender were observed. Smokers had a 24% higher rate of erlotinib clearance.

US Natl Inst Health; DailyMed. Current Medication Information for TARCEVA (erlotinib hydrochloride) tablet (April 2012). Available from, as of November 10, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20


Following a 100 mg oral dose, 91% of the dose was recovered: 83% in feces (1% of the dose as intact parent) and 8% in urine (0.3% of the dose as intact parent).

US Natl Inst Health; DailyMed. Current Medication Information for TARCEVA (erlotinib hydrochloride) tablet (April 2012). Available from, as of November 10, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20


For more Absorption, Distribution and Excretion (Complete) data for Erlotinib (10 total), please visit the HSDB record page.


5.5 Metabolism/Metabolites

Metabolism occurs in the liver. In vitro assays of cytochrome P450 metabolism showed that erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2, and the extrahepatic isoform CYP1A1.


Metabolism and excretion of erlotinib, an orally active inhibitor of epidermal growth factor receptor tyrosine kinase, were studied in healthy male volunteers after a single oral dose of (14)C-erlotinib hydrochloride (100-mg free base equivalent, approximately 91 microCi/subject)... In plasma, unchanged erlotinib represented the major circulating component, with the pharmacologically active metabolite M14 accounting for approximately 5% of the total circulating radioactivity. Three major biotransformation pathways of erlotinib are O-demethylation of the side chains followed by oxidation to a carboxylic acid, M11 (29.4% of dose); oxidation of the acetylene moiety to a carboxylic acid, M6 (21.0%); and hydroxylation of the aromatic ring to M16 (9.6%). In addition, O-demethylation of M6 to M2, O-demethylation of the side chains to M13 and M14, and conjugation of the oxidative metabolites with glucuronic acid (M3, M8, and M18) and sulfuric acid (M9) play a minor role in the metabolism of erlotinib. The identified metabolites accounted for >90% of the total radioactivity recovered in urine and feces. The metabolites observed in humans were similar to those found in the toxicity species, rats and dogs.

PMID:16381666 Ling J et al; Drug Metab Dispos 34 (3): 420-6 (2006)


Erlotinib has known human metabolites that include Erlotinib M14.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.6 Biological Half-Life

Median half-life of 36.2 hours.


A population pharmacokinetic analysis in 591 patients receiving the single-agent erlotinib hydrochloride 2nd/3rd line regimen showed a median half-life of 36.2 hours.

US Natl Inst Health; DailyMed. Current Medication Information for TARCEVA (erlotinib hydrochloride) tablet (April 2012). Available from, as of November 10, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20


5.7 Mechanism of Action

The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.


Although the exact mechanism of antineoplastic activity of erlotinib has not been fully elucidated, erlotinib appears to inhibit the intracellular phosphorylation of tyrosine kinase associated with EGFR, which is expressed on the surface of normal and cancer cells. Specificity with regard to other tyrosine kinase receptors has not been fully characterized.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 1042


Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong survival after failure of first-line or second-line chemotherapy. However, little is known about its effects on immune system. In the present study, /investigators/ aimed to investigate the immunosuppressive activity of erlotinib on T lymphocytes both in vitro and in vivo, and further explore its potential molecular mechanism. Erlotinib exerted a significant inhibition on the T cell proliferation and activation induced by concanavalin A, anti-CD3 plus anti-CD28, staphylococcal enterotoxin B or phorbol myristate acetate respectively in a concentration-dependent manner and it also inhibited the secretion of the proinflammatory cytokines such as IL-2 and IFN-gamma of activated T cells. Further study showed that erlotinib caused G0/G1 arrest and suppressed the phosphorylations of c-Raf, ERK and Akt in activated T cells. Moreover, erlotinib significantly ameliorated picryl chloride-induced ear contact dermatitis in a dose-dependent manner in vivo. In summary, these findings suggest that erlotinib may cause the impairment of T-cell-mediated immune response both in vitro and in vivo through inhibiting T cell proliferation and activation, which is closely associated with its potent down-regulation of the c-Raf/ERK cascade and Akt signaling pathway.

PMID:21195724 Luo Q et al; Toxicol Appl Pharmacol 251 (2): 130-6 (2011)


API SUPPLIERS

read-more
read-more

01

Rochem International Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Rochem

02

Gonane Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Gonane Pharma

03

HRV Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF AU, ASMF arrow-down AUDIT
HRV Global Life Sciences

04

Shandong Loncom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shandong Loncom Pharmaceutical company banner

05

Vannsh Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

COMPAMED
Not Confirmed
arrow

06

Teva Pharmaceutical Industries

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

COMPAMED
Not Confirmed
arrow

07

Sakar Healthcare

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

COMPAMED
Not Confirmed
arrow

Sakar Healthcare

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
COMPAMED
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Biotechnica DWC

Algeria

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

COMPAMED
Not Confirmed
arrow

Biotechnica DWC

Algeria

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
COMPAMED
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Polaris AI Pharma

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

COMPAMED
Not Confirmed
arrow

Polaris AI Pharma

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
COMPAMED
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Laurus Labs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

COMPAMED
Not Confirmed
arrow

Laurus Labs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
COMPAMED
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Flag U.S.A
Digital Content Digital Content

Erlotinib

About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...

Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quality ingredients manufactured in China. Headquartered in the Hauppauge, New York, Rochem has 16 offices spread across the globe to cater to the needs of its customers. Rochem’s operations are fully cGMP compliant and has been audited by the USFDA as well as several multinational organizations. It also trains and audits its partners to ensure all of their technologies and systems are FDA-compliant.
Rochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.

Flag India
Digital Content Digital Content

Erlotinib

About the Company : Gonane Pharma, is a contract pharmaceutical company located in Gujarat, India, specializing in the manufacturing and marketing of Corticosteroids, Hormones, Antivirals, and Oncolog...

Gonane Pharma, is a contract pharmaceutical company located in Gujarat, India, specializing in the manufacturing and marketing of Corticosteroids, Hormones, Antivirals, and Oncology products. The company's core strength lies in its dedicated team, and its promoters bring over 25 years of experience in manufacturing, promoting products, and managing audits for regulated markets such as the EU, Mexico, China, Korea, and Russia. GONANE PHARMA is actively engaged in discussions with Japanese customers and anticipates further expansion into additional markets.
Gonane Pharma

03

HRV Pharma

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Erlotinib

About the Company : HRV Pharma is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Pharma is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Pharma effectively promote projects and products. HRV Pharma represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Pharma has offices in the US, Switzerland, Dubai, Lithuania & Turkey.
HRV Global Life Sciences

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content

Erlotinib

About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...

Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development Zone, Shandong Province, Shandong Loncom has operational API pilot tests and production bases adhering to international standards. With 13 production lines dedicated to oral solid preparations, oral liquid preparations and API, it is actively expanding its preparation workshops for small-volume injections, soft capsules, eye drops, topical medicines and innovative drug R&D centres.
Shandong Loncom Pharmaceutical company banner

05

Aspen Bio

India
BOS Manchester
Not Confirmed
arrow

Aspen Bio

India
arrow
BOS Manchester
Not Confirmed

Erlotinib

About the Company : Aspen Bio is a multifaceted company that was established in 2014. Aspen Bio defines development and novelty as a challenge for competitive markets to provide improved health servic...

Aspen Bio is a multifaceted company that was established in 2014. Aspen Bio defines development and novelty as a challenge for competitive markets to provide improved health services to people, through pioneering Research & Development in agreement with the latest principles to ensure safe and secured wellness. The Company is established in bringing the benefit of high quality APIs & Finished Formulations, yet reasonably priced, to patients in India and other emerging markets.
blank

06

BOS Manchester
Not Confirmed
arrow
arrow
BOS Manchester
Not Confirmed

Erlotinib

About the Company : Danesh Kimia Pharmed Co. was established on 2011 by industrial and university researchers in order to invest on the production of new pharmaceutical molecules and their ready to us...

Danesh Kimia Pharmed Co. was established on 2011 by industrial and university researchers in order to invest on the production of new pharmaceutical molecules and their ready to use pharmaceutical dosage forms. The company is known as the pioneer generic producer for new entities and ready to use pharmaceutical formulations made by research and production units. It has created a production line for anticancer active ingredients in Baran Chemical and Pharmaceutical Co., molecules in low quantity with high value such as Fingolimod, Nitisinone, Bosentan, etc.
blank

07

BOS Manchester
Not Confirmed
arrow
arrow
BOS Manchester
Not Confirmed

Erlotinib

About the Company : Murli Krishna Pharma Private Ltd. is a young and dynamic drug delivery systems (DDS) company in India that provides a range of effective solutions to optimize the delivery of pharm...

Murli Krishna Pharma Private Ltd. is a young and dynamic drug delivery systems (DDS) company in India that provides a range of effective solutions to optimize the delivery of pharmaceutical products.Our manufacturing plant is approved for GMP Compliance by the WHO and the European Union; Murli Krishna Pharma is equipped to undertake formulation development projects on oral NDDS.
blank

08

BOS Manchester
Not Confirmed
arrow
arrow
BOS Manchester
Not Confirmed

Erlotinib

About the Company : Established in the year 2004, Sakar is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injec...

Established in the year 2004, Sakar is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Sakar is managed by a team of professionals with an endeavour to offer Quality Pharmaceutical & Health Care Products in various countries. The company operates as contract development and manufacturing organisation (CDMO), being the EU GMP approved CMO for leading multinational pharmaceutical companies.
blank

09

BOS Manchester
Not Confirmed
arrow
arrow
BOS Manchester
Not Confirmed

Erlotinib

About the Company : Established in 1990, we have been catering to international US FDA approved API facilities since 1996. We are thoroughly acquainted and equipped to meet client regulatory, systems,...

Established in 1990, we have been catering to international US FDA approved API facilities since 1996. We are thoroughly acquainted and equipped to meet client regulatory, systems, and process demands. Our track record includes facilitating more than 50 successful audits at supplier facilities, with a portfolio boasting over 364 approved vendors and 652 validated products. With over three decades of experience, we specialize in contract manufacturing of essential pharmaceutical intermediates.
blank

10

BOS Manchester
Not Confirmed
arrow
arrow
BOS Manchester
Not Confirmed

Erlotinib

About the Company : Headquartered in Southern California, Stason entered the commercial generic market in 1994 and today continues to manufacture and market these products through our global network o...

Headquartered in Southern California, Stason entered the commercial generic market in 1994 and today continues to manufacture and market these products through our global network of distributors. Stason entered the contract manufacturing arena in 2000 to provide manufacturing support to other pharmaceutical companies. We provide both non-high containment and high containment manufacturing services. In 2008, we launched our Brand Division when we obtained exclusive development and commercialization rights to two novel proprietary compounds in the area of oncology.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641493800,"product":"ERLOTINIB HYDROCHLORIDE BATCH NUMBER;ERL","address":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE","city":"BANGALORE,KARNATAKA","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LARNACA","customer":"TO THE CONSIGNEE","customerCountry":"CYPRUS","quantity":"31.45","actualQuantity":"31.445","unit":"KGS","unitRateFc":"2000","totalValueFC":"61629.6","currency":"USD","unitRateINR":146000.95404674829,"date":"07-Jan-2022","totalValueINR":"4591000","totalValueInUsd":"61629.6","indian_port":"BANGALORE AIR","hs_no":"29420090","bill_no":"7306234","productDescription":"API","marketType":"REGULATED MARKET","country":"CYPRUS","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641753000,"product":"ERLOTINIB HCL IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"SANTIAGO DE CHILE -","customer":"SYNTHON CHILE LTDA","customerCountry":"CHILE","quantity":"31.43","actualQuantity":"31.43","unit":"KGS","unitRateFc":"2093.8","totalValueFC":"71402.3","currency":"EURO","unitRateINR":169233.21667196945,"date":"10-Jan-2022","totalValueINR":"5319000","totalValueInUsd":"71402.3","indian_port":"HYDERABAD AIR","hs_no":"29093090","bill_no":"7374938","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641925800,"product":"ERLOTINIB HYDROCHLORIDE, BATCH-IWP210076","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"BO RYUNG PHARM CO LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"3.03","actualQuantity":"3.03","unit":"KGS","unitRateFc":"8900","totalValueFC":"24646.5","currency":"USD","unitRateINR":605940.59405940596,"date":"12-Jan-2022","totalValueINR":"1836000","totalValueInUsd":"24646.5","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"7422809","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641925800,"product":"ERLOTINIB HYDROCHLORIDE, BATCH-IWP210074","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"CHONG KUN DANG PHARM","customerCountry":"KOREA, REPUBLIC OF","quantity":"5.09","actualQuantity":"5.085","unit":"KGS","unitRateFc":"5000","totalValueFC":"24968.6","currency":"USD","unitRateINR":365781.71091445431,"date":"12-Jan-2022","totalValueINR":"1860000","totalValueInUsd":"24968.6","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"7422688","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1643394600,"product":"ERLOTINIB HYDROCHLORIDE, BATCH-IWP220005","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"BO RYUNG PHARM CO LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"7.71","actualQuantity":"7.713","unit":"KGS","unitRateFc":"8900","totalValueFC":"62784","currency":"USD","unitRateINR":606378.84091793071,"date":"29-Jan-2022","totalValueINR":"4677000","totalValueInUsd":"62784","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"7815662","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644517800,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO : IWP21","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA LTD","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"BLAU FARMACEUTICA S A","customerCountry":"BRAZIL","quantity":"7.32","actualQuantity":"7.32","unit":"KGS","unitRateFc":"3990","totalValueFC":"28723.2","currency":"USD","unitRateINR":294125.68306010927,"date":"11-Feb-2022","totalValueINR":"2153000","totalValueInUsd":"28723.2","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"8151198","productDescription":"API","marketType":"","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645641000,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO : IWP22","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA LTD","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"BLAU FARMACEUTICA S A","customerCountry":"BRAZIL","quantity":"7.64","actualQuantity":"7.64","unit":"KGS","unitRateFc":"3990","totalValueFC":"30097.3","currency":"USD","unitRateINR":295287.95811518328,"date":"24-Feb-2022","totalValueINR":"2256000","totalValueInUsd":"30097.3","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"8463998","productDescription":"API","marketType":"","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645641000,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO : IWP22","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA LTD","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"BLAU FARMACEUTICA S A","customerCountry":"BRAZIL","quantity":"7.81","actualQuantity":"7.806","unit":"KGS","unitRateFc":"3990","totalValueFC":"30751","currency":"USD","unitRateINR":295285.67768383294,"date":"24-Feb-2022","totalValueINR":"2305000","totalValueInUsd":"30751","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"8463998","productDescription":"API","marketType":"","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1646332200,"product":"ERLOTINIB HCL IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"TOKYO","customer":"NIPPON KAYAKU COLTD","customerCountry":"JAPAN","quantity":"18.00","actualQuantity":"18","unit":"KGS","unitRateFc":"12000","totalValueFC":"212242.2","currency":"USD","unitRateINR":898722.22222222225,"date":"04-Mar-2022","totalValueINR":"16177000","totalValueInUsd":"212242.2","indian_port":"HYDERABAD AIR","hs_no":"29093090","bill_no":"8696766","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647541800,"product":"ERLOTINIB HYDROCHLORIDE, BATCH-IWP220014","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"BO RYUNG PHARM CO LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"6.15","actualQuantity":"6.152","unit":"KGS","unitRateFc":"8900","totalValueFC":"49974.1","currency":"USD","unitRateINR":619148.24447334197,"date":"18-Mar-2022","totalValueINR":"3809000","totalValueInUsd":"49974.1","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"9036598","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649269800,"product":"ERLOTINIB HYDROCHLORIDE","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"UNDISCLOSED","customerCountry":"ISRAEL","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"3000","totalValueFC":"2770.1","currency":"USD","unitRateINR":209000,"date":"07-Apr-2022","totalValueINR":"209000","totalValueInUsd":"2770.1","indian_port":"AHMEDABAD AIR","hs_no":"29349990","bill_no":"9540666","productDescription":"API","marketType":"","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649701800,"product":"ERLOTINIB HYDROCHLORIDE (FORM-P) (OTHER","address":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,","city":"HYDERABAD,TELANGANA","supplier":"NATCO PHARMA LTD","supplierCountry":"INDIA","foreign_port":"ZAGREB","customer":"PLIVA HRVATSKA DOOFTOZ","customerCountry":"CROATIA","quantity":"42.00","actualQuantity":"42","unit":"KGS","unitRateFc":"4200","totalValueFC":"174555.2","currency":"USD","unitRateINR":313571.42857142858,"date":"12-Apr-2022","totalValueINR":"13170000","totalValueInUsd":"174555.2","indian_port":"HYDERABAD AIR","hs_no":"29214290","bill_no":"9635850","productDescription":"API","marketType":"REGULATED MARKET","country":"CROATIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1651861800,"product":"ERLOTINIB HCL IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"TOKYO - NARITA","customer":"UNDISCLOSED","customerCountry":"JAPAN","quantity":"36.00","actualQuantity":"36","unit":"KGS","unitRateFc":"5000","totalValueFC":"175181.1","currency":"USD","unitRateINR":376083.33333333331,"date":"07-May-2022","totalValueINR":"13539000","totalValueInUsd":"175181.1","indian_port":"HYDERABAD AIR","hs_no":"29093090","bill_no":"1238864","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652725800,"product":"ERLOTINIB HCL IH (FORM A)","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"4122.5","totalValueFC":"11916.8","currency":"USD","unitRateINR":307000,"date":"17-May-2022","totalValueINR":"921000","totalValueInUsd":"11916.8","indian_port":"HYDERABAD AIR","hs_no":"29093090","bill_no":"1435672","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653503400,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO;ERLE200","address":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE","city":"BANGALORE,KARNATAKA","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"KONGIGANAK","customer":"UNDISCLOSED","customerCountry":"SAUDI ARABIA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"1700","totalValueFC":"3273.6","currency":"USD","unitRateINR":126500,"date":"26-May-2022","totalValueINR":"253000","totalValueInUsd":"3273.6","indian_port":"BANGALORE AIR","hs_no":"29420090","bill_no":"1666482","productDescription":"API","marketType":"","country":"SAUDI ARABIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662661800,"product":"ERLOTINIB HCL IH (FORM A) BATCH NOS:ED2","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"3.60","actualQuantity":"3.6","unit":"KGS","unitRateFc":"4030","totalValueFC":"14100.1","currency":"USD","unitRateINR":313888.88888888888,"date":"09-Sep-2022","totalValueINR":"1130000","totalValueInUsd":"14100.1","indian_port":"HYDERABAD AIR","hs_no":"29093090","bill_no":"4078781","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663180200,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO;ERLC001","address":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE","city":"BANGALORE,KARNATAKA","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"LABORATORIO ECZANE PHARMA S A","customerCountry":"ARGENTINA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"2500","totalValueFC":"1909.1","currency":"USD","unitRateINR":153000,"date":"15-Sep-2022","totalValueINR":"153000","totalValueInUsd":"1909.1","indian_port":"BANGALORE AIR","hs_no":"29420090","bill_no":"4205357","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1664821800,"product":"ERLOTINIB HCL IH (FORM A) (AS PER INVOIC","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"SANTIAGO DE CHILE -","customer":"UNDISCLOSED","customerCountry":"CHILE","quantity":"33.93","actualQuantity":"33.93","unit":"KGS","unitRateFc":"2500","totalValueFC":"80246.3","currency":"USD","unitRateINR":194606.54288240496,"date":"04-Oct-2022","totalValueINR":"6603000","totalValueInUsd":"80246.3","indian_port":"HYDERABAD AIR","hs_no":"29093090","bill_no":"4615428","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1666204200,"product":"ERLOTINIB HCL IH (FORM A)","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"3800","totalValueFC":"18484.7","currency":"USD","unitRateINR":304200,"date":"20-Oct-2022","totalValueINR":"1521000","totalValueInUsd":"18484.7","indian_port":"HYDERABAD AIR","hs_no":"29093090","bill_no":"4956748","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1666377000,"product":"ERLOTINIB HCL","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"UNDISCLOSED","customerCountry":"VIETNAM","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"3334","totalValueFC":"461.8","currency":"USD","unitRateINR":253333.33333333334,"date":"22-Oct-2022","totalValueINR":"38000","totalValueInUsd":"461.8","indian_port":"HYDERABAD AIR","hs_no":"29093090","bill_no":"5010850","productDescription":"API","marketType":"","country":"VIETNAM, DEMOCRATIC REP. OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1671042600,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO : IWP22","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA LTD","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"BLAU FARMACEUTICA S A","customerCountry":"BRAZIL","quantity":"0.98","actualQuantity":"0.98","unit":"KGS","unitRateFc":"3990","totalValueFC":"3604.1","currency":"USD","unitRateINR":303061.22448979592,"date":"15-Dec-2022","totalValueINR":"297000","totalValueInUsd":"3604.1","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"6180456","productDescription":"API","marketType":"","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674585000,"product":"ERLOTINIB HYDROCHLORIDE BATCH NUMBER;ERL","address":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE","city":"BANGALORE,KARNATAKA","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LARNACA","customer":"M SREMEDICA LTD","customerCountry":"CYPRUS","quantity":"39.14","actualQuantity":"39.14","unit":"KGS","unitRateFc":"2000","totalValueFC":"76492.7","currency":"USD","unitRateINR":159785.38579458353,"date":"25-Jan-2023","totalValueINR":"6254000","totalValueInUsd":"76492.7","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"7246618","productDescription":"API","marketType":"REGULATED MARKET","country":"CYPRUS","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675881000,"product":"ERLOTINIB HYDROCHLORIDE (FORM P) (APPEND","address":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,","city":"HYDERABAD,TELANGANA","supplier":"NATCO PHARMA LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"TEVA CANADA LTD","customerCountry":"CANADA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"7500","totalValueFC":"164002.9","currency":"CAD","unitRateINR":451500,"date":"09-Feb-2023","totalValueINR":"13545000","totalValueInUsd":"164002.9","indian_port":"HYDERABAD AIR","hs_no":"29214290","bill_no":"7658772","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675967400,"product":"ERLOTINIB HYDROCHLORIDE (INTAS)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,,","city":"AHMEDABAD,GUJARAT","supplier":"INTAS PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"FARMABIOT S A DE CV AA NANCY","customerCountry":"MEXICO","quantity":"50.00","actualQuantity":"50","unit":"KGS","unitRateFc":"1516.1","totalValueFC":"74392.1","currency":"USD","unitRateINR":122880.84,"date":"10-Feb-2023","totalValueINR":"6144042","totalValueInUsd":"74392.1","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29335990","bill_no":"4000821","productDescription":"API","marketType":"","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad-ZIPL-SEZ","supplierAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678300200,"product":"ERLOTINIB HYDROCHLORIDE(40GM & 10 GM)(TA","address":"4A, AMAN ADHAR SOCIETY OPP. KALAWAT, WARASIYA RING ROAD CO","city":"VADODARA","supplier":"GLOBAUX IMPEX PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"UNDISCLOSED","customerCountry":"CANADA","quantity":"0.05","actualQuantity":"50","unit":"GMS","unitRateFc":"600","totalValueFC":"559.3","currency":"USD","unitRateINR":920,"date":"09-Mar-2023","totalValueINR":"46000","totalValueInUsd":"559.3","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"8333800","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"4A, AMAN ADHAR SOCIETY OPP. KALAWAT, WARASIYA RING ROAD CO, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1679250600,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO;ERLC001","address":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE","city":"BANGALORE,KARNATAKA","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"LLC BRATSKCHEMSYNTEZ","customerCountry":"RUSSIA","quantity":"13.50","actualQuantity":"13.5","unit":"KGS","unitRateFc":"132128","totalValueFC":"21349.4","currency":"INR","unitRateINR":130074.07407407407,"date":"20-Mar-2023","totalValueINR":"1756000","totalValueInUsd":"21349.4","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"8606759","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1687285800,"product":"ERLOTINIB HYDROCHLORIDE (FORM P)(APPENDI","address":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,","city":"HYDERABAD,TELANGANA","supplier":"NATCO PHARMA LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"TEVA CANADA LTD","customerCountry":"CANADA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"7500","totalValueFC":"16460.6","currency":"CAD","unitRateINR":451000.09499999997,"date":"21-Jun-2023","totalValueINR":"1353000.285","totalValueInUsd":"16460.6","indian_port":"HYDERABAD AIR","hs_no":"29214290","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1688063400,"product":"ERLOTINIB HYDROCHLORIDE BATCH NOS:EB0030","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"2861.5","totalValueFC":"28200.8","currency":"USD","unitRateINR":231800.01389999999,"date":"30-Jun-2023","totalValueINR":"2318000.139","totalValueInUsd":"28200.8","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"0","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690655400,"product":"BULK DRUG(ERLOTINIB HYDROCHLORIDE)","address":"","city":"","supplier":"SHILPA PHARMA LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"RELIV PHARMACEUTICAL JOINT STOCK CO","customerCountry":"VIETNAM","quantity":"10.50","actualQuantity":"10.5","unit":"KGS","unitRateFc":"4405","totalValueFC":"45662.8","currency":"USD","unitRateINR":357428.60399999999,"date":"30-Jul-2023","totalValueINR":"3753000.342","totalValueInUsd":"45662.8","indian_port":"MADRAS AIR","hs_no":"29349990","bill_no":"0","productDescription":"API","marketType":"","country":"VIETNAM, DEMOCRATIC REP. OF","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRAS AIR","supplierAddress":"","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692556200,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO;ERLC001","address":"N0 116\/117 KIADB INDUSTRIAL AREA JIGANI 2ND PHASE","city":"BANGALORE","supplier":"ACEBRIGHT INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"LABORATORIO ECZANE PHARMA S A","customerCountry":"ARGENTINA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"2500","totalValueFC":"2096.3","currency":"USD","unitRateINR":173652.432,"date":"21-Aug-2023","totalValueINR":"173652.432","totalValueInUsd":"2096.3","indian_port":"BANGALORE AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"N0 116\/117 KIADB INDUSTRIAL AREA JIGANI 2ND PHASE, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696876200,"product":"ERLOTINIB HCL IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"21.00","actualQuantity":"21","unit":"KGS","unitRateFc":"2700","totalValueFC":"56074","currency":"USD","unitRateINR":222238.09523809524,"date":"10-Oct-2023","totalValueINR":"4667000","totalValueInUsd":"56074","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"4539932","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696962600,"product":"ERLOTINIB HCL FORM -A IH","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"2600","totalValueFC":"30791.1","currency":"USD","unitRateINR":213559.83333333334,"date":"11-Oct-2023","totalValueINR":"2562718","totalValueInUsd":"30791.1","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"4547689","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697135400,"product":"ERLOTINIB HYDROCHLORIDE FORMA-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"3977","totalValueFC":"19680.6","currency":"USD","unitRateINR":327600,"date":"13-Oct-2023","totalValueINR":"1638000","totalValueInUsd":"19680.6","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"4611192","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1700245800,"product":"ERLOTINIB HCL FORM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"45.00","actualQuantity":"45","unit":"KGS","unitRateFc":"2700","totalValueFC":"119885.8","currency":"USD","unitRateINR":221844.44444444444,"date":"18-Nov-2023","totalValueINR":"9983000","totalValueInUsd":"119885.8","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"5422864","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703615400,"product":"ERLOTINIB HCL FORM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"BINH DINH PHARMACEUTICAL AND MEDICA","customerCountry":"VIETNAM","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"4000","totalValueFC":"1958.1","currency":"USD","unitRateINR":326000,"date":"27-Dec-2023","totalValueINR":"163000","totalValueInUsd":"1958.1","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"6344394","productDescription":"API","marketType":"","country":"VIETNAM, DEMOCRATIC REP. OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704393000,"product":"ERLOTINIB HCL FORM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"ALMATY","customer":"JSC NOBEL ALMATINSKAYA FARMAZEVTICH","customerCountry":"KAZAKHSTAN","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"2700","totalValueFC":"10631.6","currency":"USD","unitRateINR":220903,"date":"05-Jan-2024","totalValueINR":"883612","totalValueInUsd":"10631.6","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"6534463","productDescription":"API","marketType":"","country":"KAZAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710268200,"product":"ERLOTINIB HCL IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"JAKARTA","customer":"UNDISCLOSED","customerCountry":"INDONESIA","quantity":"1.10","actualQuantity":"1.1","unit":"KGS","unitRateFc":"2400","totalValueFC":"2575.7","currency":"USD","unitRateINR":194433.63636363635,"date":"13-Mar-2024","totalValueINR":"213877","totalValueInUsd":"2575.7","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"8287164","productDescription":"API","marketType":"","country":"INDONESIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710873000,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO;ERLD23016P1","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"LABORATORIO ECZANE PHARMA S A","customerCountry":"ARGENTINA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"2400","totalValueFC":"6528.6","currency":"USD","unitRateINR":180701.60000000001,"date":"20-Mar-2024","totalValueINR":"542104.8","totalValueInUsd":"6528.6","indian_port":"Bangalore Air","hs_no":"29335990","bill_no":"8474055","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713810600,"product":"ERLOTINIB HYDROCHLORIDE PO NO;109157 BATCH NO;ERLD23015P1","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LARNACA","customer":"REMEDICA LTD","customerCountry":"CYPRUS","quantity":"13.70","actualQuantity":"13.695","unit":"KGS","unitRateFc":"1900","totalValueFC":"25599.6","currency":"USD","unitRateINR":156097.62029937934,"date":"23-Apr-2024","totalValueINR":"2137756.91","totalValueInUsd":"25599.6","indian_port":"Bangalore Air","hs_no":"29335990","bill_no":"9335085","productDescription":"API","marketType":"REGULATED MARKET","country":"CYPRUS","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716143400,"product":"ERLOTINIB HCL FORM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"UNDISCLOSED","customerCountry":"EGYPT","quantity":"14.00","actualQuantity":"14","unit":"KGS","unitRateFc":"3600","totalValueFC":"49894.8","currency":"USD","unitRateINR":297067.28571428574,"date":"20-May-2024","totalValueINR":"4158942","totalValueInUsd":"49894.8","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"1009822","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725215400,"product":"ERLOTINIB HYDROCHLORIDE IH (PACK: 2KG)(BULK DRUG)","address":"79\/87 D LAD PATH","city":"MUMBAI, MAHARASHTRA","supplier":"KHANDELWAL LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISLAMABAD - ISLAMABA","customer":"ROTEX PHARMA PVT LTD","customerCountry":"PAKISTAN","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"1000","totalValueFC":"1981.6","currency":"USD","unitRateINR":83030.764999999999,"date":"02-Sep-2024","totalValueINR":"166061.53","totalValueInUsd":"1981.6","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"3693555","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"79\/87 D LAD PATH, MUMBAI, MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729017000,"product":"PHARMA INGREDIENTS - ERLOTINIB HYDROCHLORIDE IN-HOUSE","address":"30, AROHI VILLA, S.P. RING ROAD, BOPAL,","city":"AHMEDABAD","supplier":"GREENCROSS EXPORT PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"5000","totalValueFC":"24417.7","currency":"USD","unitRateINR":410347.79999999999,"date":"16-Oct-2024","totalValueINR":"2051739","totalValueInUsd":"24417.7","indian_port":"Ahmedabad Air","hs_no":"29339990","bill_no":"4846026","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"30, AROHI VILLA, S.P. RING ROAD, BOPAL,, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732905000,"product":"ERLOTINIB HYDROCHLORIDE","address":"202,KUNTAL,MODY ESTATES,L.B.S.MARG,","city":"MUMBAI, MAHARASHTRA.","supplier":"THYKN INDIA INTERNATIONAL","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"TO ORDER OF","customerCountry":"VIETNAM","quantity":"17.00","actualQuantity":"17","unit":"KGS","unitRateFc":"2500","totalValueFC":"41697","currency":"USD","unitRateINR":206984.25647058824,"date":"30-Nov-2024","totalValueINR":"3518732.36","totalValueInUsd":"41697","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"6059075","productDescription":"API","marketType":"","country":"VIETNAM","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"202,KUNTAL,MODY ESTATES,L.B.S.MARG,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1736965800,"product":"ERLOTINIB HYDROCHLORIDE BATCH NO;ERLD23016P1,ERLD24001P1 & ERLD24002P1","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LARNACA","customer":"REMEDICA LTD","customerCountry":"CYPRUS","quantity":"93.21","actualQuantity":"93.21","unit":"KGS","unitRateFc":"1900","totalValueFC":"173114.1","currency":"USD","unitRateINR":160149.04248471194,"date":"16-Jan-2025","totalValueINR":"14927492.25","totalValueInUsd":"173114.1","indian_port":"Bangalore Air","hs_no":"29335990","bill_no":"7322285","productDescription":"API","marketType":"REGULATED MARKET","country":"CYPRUS","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1744828200,"product":"ERLOTINIB HCL FORM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"SANTIAGO","customer":"SYNTHON CHILE LTDA","customerCountry":"CHILE","quantity":"27.00","actualQuantity":"27","unit":"KGS","unitRateFc":"2300","totalValueFC":"60512.6","currency":"USD","unitRateINR":191851.48666666666,"date":"17-Apr-2025","totalValueINR":"5179990.14","totalValueInUsd":"60512.6","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"1021190","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745001000,"product":"ERLOTINIB HYDROCHLORIDE (ERLOTINIB HCL)","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"RELIV PHARMACEUTICAL JOINT STOCK CO","customerCountry":"VIETNAM","quantity":"19.50","actualQuantity":"19.5","unit":"KGS","unitRateFc":"1380","totalValueFC":"26536.1","currency":"USD","unitRateINR":116489.02564102564,"date":"19-Apr-2025","totalValueINR":"2271536","totalValueInUsd":"26536.1","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"1097587","productDescription":"API","marketType":"","country":"VIETNAM","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748025000,"product":"ERLOTINIB HCL FORM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"ASCLEPIUS","customerCountry":"UNITED ARAB EMIRATES","quantity":"8.00","actualQuantity":"8","unit":"KGS","unitRateFc":"2300","totalValueFC":"20311.1","currency":"EURO","unitRateINR":216315,"date":"24-May-2025","totalValueINR":"1730520","totalValueInUsd":"20311.1","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"2112685","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1756837800,"product":"ERLOTINIB HCL IH","address":"HETERO CORPORATE, NO. 7-2-A2,,INDU","city":"HYDERABAD,TELANGANA","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"TOKYO - NARITA","customer":"UNDISCLOSED","customerCountry":"JAPAN","quantity":"35.00","actualQuantity":"35","unit":"KGS","unitRateFc":"4900","totalValueFC":"167128.8","currency":"USD","unitRateINR":421494.28571428574,"date":"03-Sep-2025","totalValueINR":"14752300","totalValueInUsd":"167128.8","indian_port":"Hyderabad Air","hs_no":"29093090","bill_no":"4994466","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,,INDU, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645381800,"product":"REIMPORT-ERLOTINIB HCL IH (FORM A) (SB NO: 5349639 \/ DATE: 22.09.2020)","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"SYNTHON CHILE LTDA","supplierCountry":"INDIA","foreign_port":"NA","customer":"HETERO LABS LTD","customerCountry":"INDIA","quantity":"19.79","actualQuantity":"19.793","unit":"KGS","unitRateFc":"2500","totalValueFC":"50212.1","currency":"USD","unitRateINR":"190155.4","date":"21-Feb-2022","totalValueINR":"3763746.23","totalValueInUsd":"50212.1","indian_port":"MADRAS AIR","hs_no":"29093090","bill_no":"7591326","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta"}]
07-Jan-2022
03-Sep-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Europe

read-more
read-more

01

Erlotinibhydroklorid

Brand Name : Erlotinib Orion

Dosage Form : Film Coated Tablet

Dosage Strength : 100mg

Packaging :

Approval Date : 15/01/2019

Application Number : 20171220000027

Regulatory Info : Deregistered

Registration Country : Sweden

Fermion Orion Company Banner

02

Erlotinibhydroklorid

Brand Name : Erlotinib Orion

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date : 15/01/2019

Application Number : 20171220000034

Regulatory Info : Deregistered

Registration Country : Sweden

Fermion Orion Company Banner

03

Erlotinibhydroklorid

Brand Name : Erlotinib Orion

Dosage Form : Film Coated Tablet

Dosage Strength : 25mg

Packaging :

Approval Date : 15/01/2019

Application Number : 20171220000010

Regulatory Info : Deregistered

Registration Country : Sweden

Fermion Orion Company Banner

04

COMPAMED
Not Confirmed
arrow
arrow
COMPAMED
Not Confirmed

Erlotinibhydroklorid

Brand Name : Tarceva

Dosage Form : Film Coated Tablet

Dosage Strength : 100mg

Packaging :

Approval Date : 19/09/2005

Application Number : 20041013000025

Regulatory Info : Approved

Registration Country : Sweden

blank

05

COMPAMED
Not Confirmed
arrow
arrow
COMPAMED
Not Confirmed

Erlotinibhydroklorid

Brand Name : Erlotinib Glenmark

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date : 15/03/2019

Application Number : 20181119000069

Regulatory Info : Deregistered

Registration Country : Sweden

blank

06

COMPAMED
Not Confirmed
arrow
arrow
COMPAMED
Not Confirmed

Erlotinibhydroklorid

Brand Name : Erlotinib Medical Valley

Dosage Form : Film Coated Tablet

Dosage Strength : 25mg

Packaging :

Approval Date : 29/04/2019

Application Number : 20180403000037

Regulatory Info : Approved

Registration Country : Sweden

blank

07

COMPAMED
Not Confirmed
arrow
arrow
COMPAMED
Not Confirmed

Erlotinib

Brand Name : Ertinob

Dosage Form : Film Coated Tablet

Dosage Strength : 25MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Turkey

blank

08

UQUIFA

Spain
COMPAMED
Not Confirmed
arrow

UQUIFA

Spain
arrow
COMPAMED
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : Tablet

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Europe

blank

09

Zentiva Ks

Czech Republic
COMPAMED
Not Confirmed
arrow

Zentiva Ks

Czech Republic
arrow
COMPAMED
Not Confirmed

Erlotinibhydroklorid

Brand Name : Erlotinib Zentiva

Dosage Form : Film Coated Tablet

Dosage Strength : 25mg

Packaging :

Approval Date : 06/05/2020

Application Number : 20191206000094

Regulatory Info : Deregistered

Registration Country : Sweden

blank

10

Central Procurement & Supplies Unit

Country
COMPAMED
Not Confirmed
arrow

Central Procurement & Supplies Unit

Country
arrow
COMPAMED
Not Confirmed

Erlotinib Hydrochloride

Brand Name : Erlotinib Tarbis

Dosage Form : Film Coated Tablet

Dosage Strength : 25MG

Packaging :

Approval Date : 2025-01-21

Application Number :

Regulatory Info : Authorised

Registration Country : Malta

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : TABLET

Dosage Strength : 25MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : India

blank

01

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : TABLET

Dosage Strength : 25MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

02

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : Tablet

Dosage Strength : 150MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : India

blank

02

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : Tablet

Dosage Strength : 150MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

03

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : Tablet

Dosage Strength : 150MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

03

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : Tablet

Dosage Strength : 150MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

04

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : Film Coated Tablet

Dosage Strength : 100MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

04

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : Film Coated Tablet

Dosage Strength : 100MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

05

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : Film Coated Tablet

Dosage Strength : 150MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

05

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : Film Coated Tablet

Dosage Strength : 150MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

06

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : Tablet

Dosage Strength : 150MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : India

blank

06

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : Tablet

Dosage Strength : 150MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

07

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name : Erlotinib Eczane

Dosage Form : Tablet

Dosage Strength : 150MG

Packaging : 30 Tabs

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Argentina

blank

07

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : Tablet

Dosage Strength : 150MG

Brand Name : Erlotinib Eczane

Approval Date :

Application Number :

Registration Country : Argentina

blank

08

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : Tablets

Dosage Strength : 150MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

08

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : Tablets

Dosage Strength : 150MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

09

Pluviaendo

Turkey
Pharmtech & Ingredients
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : Tablet

Dosage Strength : 150MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Turkey

blank

09

Pluviaendo

Turkey
Pharmtech & Ingredients
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : Tablet

Dosage Strength : 150MG

Brand Name :

Approval Date :

Application Number :

Registration Country : Turkey

blank

10

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Brand Name :

Dosage Form : Tablet

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

10

Pharmtech & Ingredients
Not Confirmed
arrow
arrow
Pharmtech & Ingredients
Not Confirmed

Erlotinib

Dosage : Tablet

Dosage Strength : 150mg

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 183321-74-6 / Erlotinib API manufacturers, exporters & distributors?

Erlotinib manufacturers, exporters & distributors 1

63

PharmaCompass offers a list of Erlotinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Erlotinib manufacturer or Erlotinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Erlotinib manufacturer or Erlotinib supplier.

PharmaCompass also assists you with knowing the Erlotinib API Price utilized in the formulation of products. Erlotinib API Price is not always fixed or binding as the Erlotinib Price is obtained through a variety of data sources. The Erlotinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Erlotinib

Synonyms

183321-74-6, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, Tarceva, Erlotinib free base, 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline, Osi-774

Cas Number

183321-74-6

Unique Ingredient Identifier (UNII)

J4T82NDH7E

About Erlotinib

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

Erlotinib Manufacturers

A Erlotinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Erlotinib, including repackagers and relabelers. The FDA regulates Erlotinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Erlotinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Erlotinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Erlotinib Suppliers

A Erlotinib supplier is an individual or a company that provides Erlotinib active pharmaceutical ingredient (API) or Erlotinib finished formulations upon request. The Erlotinib suppliers may include Erlotinib API manufacturers, exporters, distributors and traders.

click here to find a list of Erlotinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Erlotinib GMP

Erlotinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Erlotinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Erlotinib GMP manufacturer or Erlotinib GMP API supplier for your needs.

Erlotinib CoA

A Erlotinib CoA (Certificate of Analysis) is a formal document that attests to Erlotinib's compliance with Erlotinib specifications and serves as a tool for batch-level quality control.

Erlotinib CoA mostly includes findings from lab analyses of a specific batch. For each Erlotinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Erlotinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Erlotinib EP), Erlotinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Erlotinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty